ANI Pharmaceuticals Publishes Phase 4 NEW DAY Study Results for ILUVIEN in DME Patients
ANI Pharmaceuticals has published results from its randomized Phase 4 NEW DAY clinical trial of the 0.19 mg ILUVIEN implant for diabetic macular edema in the journal Ophthalmology. The study confirms ILUVIEN’s role as baseline therapy in DME patients previously treated with corticosteroids without significant intraocular pressure rise.
1. Publication of NEW DAY Results
ANI Pharmaceuticals published the randomized Phase 4 NEW DAY study results on April 7 in Ophthalmology, the American Academy of Ophthalmology’s peer-reviewed journal. This marks the first peer-reviewed dissemination of data evaluating ILUVIEN as baseline therapy for diabetic macular edema.
2. Trial Design and Findings
The NEW DAY trial enrolled DME patients previously treated with corticosteroids who did not experience clinically significant intraocular pressure increases. The study assessed the 0.19 mg fluocinolone acetonide intravitreal implant’s efficacy and safety profile over a defined follow-up period.
3. ILUVIEN Therapy Background
ILUVIEN is indicated for diabetic macular edema in patients with prior corticosteroid exposure and stable intraocular pressure. The implant delivers fluocinolone acetonide over several months, aiming to reduce macular swelling and preserve vision in chronic DME cases.
4. Commercial Implications
Publication in a leading ophthalmology journal may bolster ILUVIEN’s profile among retina specialists and support market uptake. Positive dissemination of Phase 4 data could inform prescribing patterns and strengthen ANI Pharmaceuticals’ commercial position in the DME segment.